ENTPD1 and breast carcinoma: Breast cancer patients with positive clinical outcomes exhibited low expression of CD39 and CD73 compared to patients with poorer clinical outcomes, which indicates that CD39 and CD73 can serve as biomarkers of patients' progress (152–154).